A breakthrough in preclinical data puts CK Life Sciences at the forefront of next-gen immuno-oncology. Abstract 853: ...

Researchers at Cold Spring Harbor Laboratory have found that blocking the FGFR2 and EGFR genes can stop early-stage ...

Researchers have developed an innovative nano-immune agonist that significantly improves immunotherapy outcomes for melanoma—a highly aggressive and hard-to-treat form of skin cancer.

Mohs surgery vs conventional excision was associated with decreased rates of reconstruction with positive margins for hand and foot melanoma.